Event 
Partner 
Milestone 
2019-10-29
ACT Genomics Works with UC San Diego Team to Predict Immunotherapy Response from Tumor Microenvironment (TME)
ACT Genomics and UC San Diego Moores Cancer Center have launched a study to evaluate gene expressions associated with the tumor microenvironment (TME) in PD-1 treatment outcome prediction for 100 melanoma patients. The study relies on a proprietary chip-b
Place:
Taiwan
2019-07-29
ACT Genomics Collaborates with AIA Hong Kong to Promote Precision Cancer Medicine!
ACT Genomics is excited to collaborate with AIA Hong Kong to bring ACT Genomics’ leading cancer profiling service to AIA Hong Kong customers.
Place:
Taiwan
2019-07-24
Welcome to Visit Us at BioAsia-Taiwan at M228
ACTGenomics presents precision medicine and cancer genomic profiling services at M228 in BioAsia-Taiwan. Welcome to visit us.
Place:
Taipei
2019-07-18
ACT Genomics Wins Taiwan Bio Industry Organization Awards- Emerging Company of the Year
ACT Genomics drives innovation in global standard and individual markets, winning Taiwan Bio Industry Organization Awards- Emerging Company of the Year.
Place:
Taipei
2019-07-05
ACT Genomics Opens Third Laboratory in Asia at Hong Kong Science Park
ACT Genomics Holdings Co., Ltd, a leading cancer precision treatment solution provider, opened its third Next Generation Sequencing (“NGS”) laboratory in Asia at the Hong Kong Science Park, an innovation and technology centre spearheaded by HKSTP.
Place:
Hong Kong
2019-04-19
ACT Genomics Establishes NGS Laboratory to Offer Comprehensive Cancer Genomic Profiling Service in Japan
More precision cancer medicine are available for clinical needs and drug development in Japan! Find out more at the new analysis laboratory "Shonan iPark Laboratory" of ACTmed, a joint venture between Canon Medical Systems and ACT Genomics in Japan.
Place:
Japan
2019-03-07
New Panel Launched: ACTBRCA HRD
ACTBRCA HRD is a new panel that sequences 48 genes including germline and somatic BRCA1/2, as well as other homologous recombination repair (HRR) genes, to assist physicians in identifying more patients for PARP inhibitors.
Place:
2018-12-05
ACTOnco+ received National Innovation Award in Taiwan!
ACTOnco+ won the National Innovation Award in the the Precision Medicine section in Taiwan. ACTOnco+ was awarded for providing actionable solutions to cancer patients around Asia.
Place:
Taiwan
2018-12-04
Come meet us at the Precision Medicine World Conference in Silicon Valley!
Chief Scientific Officer Dr. Shu Jen Chen will be presenting on "Biomarker Solution for Immunotherapy: TMB and Beyond" at the 16th PMWC on Jan 22nd, focusing on TMB and Tumor Micro-environment.
Place:
Silicon Valley, CA
2018-11-24
ACT Genomics Completed Another Round of Equity Financing
ACT Genomics is pleased to announce the completion of the latest round of equity financing from a group of international investors co-led by CLSA Capital Partners to support the establishment of new CAP-accredited lab in HK, as well as R&D effort.
Place:
